Real-World Implementation, Feasibility, and Early Clinical Effectiveness of Blinatumomab for Children with B-ALL in Lower Middle-Income Countries. (PubMed, Blood Adv) - Sep 11, 2026 - "MRD-negative status after cycle 1 was associated with superior 12-month EFS (P < 0.0001) and OS (P = 0.0366). With implementation support, blinatumomab was safely and effectively delivered in pediatric referral centers in lower-middle-income countries, supporting strategies to broaden immunotherapy access globally."
Journal • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Transplantation
|
|
Aqeela Rashid; Caitlyn Duffy; Carlos Rodriguez-Galindo; Gaurav Narula; Heather M Brandt; Hilmarie Muniz-Talavera; Hiroto Inaba; Lan Ngoc Bui; Linh T Pham; Meenakshi Devidas; Muhammad Rafie Raza; Nickhill Bhakta; Niharendu Ghara; Sima Jeha; Victor M Santana; Yichen Chen; Zehra Fadoo
|